Piyasa kapalı· · USD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward late-stage and commercial-stage names. All three of the highlighted stocks are positioned to launch products with significant peak sales potential.
The Shared Goals: Navigating Alzheimer’s Agitation survey finds that Alzheimer’s disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care partners reported that agitation negatively impacted their loved one’s quality of life, and three in four wish they had recognized symptoms sooner Results from the survey were recently presented at Psych Congress 2026 in New Orleans, Louisiana Survey conducted by The Harris Poll and in collaboration wi
Axsome Therapeutics has turned into a much bigger story on the market over the past few years, and the question now is whether the current share price can be squared with the sales that support it. For investors watching the recent swings, the key issue is how much revenue power is already baked into today’s valuation. Over the past 5 years the stock has delivered a very large total return of about 7x, which puts a lot of focus on whether that move is backed by the company’s underlying sales...
Earlier this week, Axsome Therapeutics highlighted new clinical data in major depressive disorder and Alzheimer’s disease agitation at Psych Congress 2026 in New Orleans, including outcomes for its dextromethorphan-bupropion therapy. By showcasing fresh and encore data across its psychiatry and neurology portfolio, Axsome put the breadth of its central nervous system pipeline in front of a clinically focused audience that can influence real-world adoption. We’ll now examine how this new...
Axsome Therapeutics (NasdaqGM:AXSM) reported new clinical data in major depressive disorder and Alzheimer’s disease agitation at a leading psychiatry congress. The presentations focused on key programs in Axsome’s central nervous system pipeline aimed at treating mood and neuropsychiatric symptoms. Management highlighted how the new findings may inform future study designs and regulatory interactions for these indications. These fresh data in depression and Alzheimer’s agitation only capture...
NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data in major depressive disorder and Alzheimer’s disease agitation and eight additional encore data posters spanning its psychiatry and neurology portfolio at Psych Congress 2026, being held September 15-19, in New Orleans, Louisiana. Details of the data presentations
Citing Bloomberg Symphony figures for the 30-milligram starter dose used when doctors begin treatment, a Mizuho analyst said new prescriptions for Auvelity rose 32% from July to August.
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in September: Wells Fargo 21st Annual Healthcare Conference Fireside Chat: Wednesday, September 9, 2026, at 3:45 p.m. ET in Boston, MA 2026 Cantor Global Healthcare Conference Fireside Chat: Thursday, September 10, 2026
NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation. SUMMIT (Studying NMDA and Sigma-1 in Smoking Cessation Treatment) is a Phase 3 randomized, double-blind, active- and placebo-controlled, multicenter trial to assess the efficacy and safety of A
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.